BridgeMD
New treatment option for Nausea
Official title A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
ClinicalTrials.gov ID: NCT07169851
What this study is testing
What is LY3537021?
LY3537021 is an investigational medicine, given as an injection under the skin, being studied as a potential treatment for nausea.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The purpose of this study is to check how well LY35327021 works and how safe it is for controlling nausea and vomiting caused by chemotherapy. Participants who join this study will be in it until all parts are finished, which could take about 2 months.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Chemotherapy-naive participants, planned to receive AC or cisplatin-based chemotherapy greater than or equal to (≥)70 milligrams per square meter...
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
You likely can't join if
- Have symptomatic or untreated central nervous system (CNS) metastases.
- Have an established diagnosis of uncontrolled diabetes mellitus.
- Have a history of, or current evidence of, a clinically significant cardiac condition or QT/QTcF-related conditions.
- Have another etiology for nausea and vomiting, or receives medications with know or potential antiemetic activity
- Signs, symptoms or history of thyroid tumors
- Receives treatment with a gastric inhibitory polypetide (GIP) or glucagon-like peptide-1 (GLP-1) receptor agonist within 4 weeks prior to...
See the full eligibility criteria
- Chemotherapy-naive participants, planned to receive AC or cisplatin-based chemotherapy greater than or equal to (≥)70 milligrams per square meter (mg/m²), on Day 1 of each cycle, with no multiple administrations during...
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
- Have symptomatic or untreated central nervous system (CNS) metastases.
- Have an established diagnosis of uncontrolled diabetes mellitus.
- Have a history of, or current evidence of, a clinically significant cardiac condition or QT/QTcF-related conditions.
- Have another etiology for nausea and vomiting, or receives medications with know or potential antiemetic activity
- Signs, symptoms or history of thyroid tumors
- Receives treatment with a gastric inhibitory polypetide (GIP) or glucagon-like peptide-1 (GLP-1) receptor agonist within 4 weeks prior to chemotherapy.
- Have participated in a clinical study involving study intervention within 30 days of Cycle 1 Day 1 (C1D1). If the previous study intervention has a long half-life, within 3 months or 5 halflives, whichever is longer, of...
- Are pregnant, breastfeeding, or intend to become pregnant during the study or within 30 days of the last dose of study intervention.
The study team makes the final eligibility decision.
Where it's taking place
- Greenbrae, California, United States
- Irvine, California, United States
- Los Alamitos, California, United States
- Walnut Creek, California, United States
- Fort Collins, Colorado, United States
- Miami Lakes, Florida, United States
- Tamarac, Florida, United States
- Savannah, Georgia, United States
- Hinsdale, Illinois, United States
- Indianapolis, Indiana, United States
- Tupelo, Mississippi, United States
- New York, New York, United States
- Shirley, New York, United States
- Charlotte, North Carolina, United States
- Huntersville, North Carolina, United States
- Medford, Oregon, United States
- Baytown, Texas, United States
- Fort Worth, Texas, United States
- Ogden, Utah, United States
- Spokane, Washington, United States
+ 42 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Greenbrae, California, United States; Irvine, California, United States; Los Alamitos, California, United States; Walnut Creek, California, United States; Fort Collins, Colorado, United States; Miami Lakes, Florida, United States and 56 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.